Core Viewpoint - Dechra Pharmaceuticals-B (06996) has seen a significant increase in stock price, rising over 10% in the afternoon trading session, reflecting positive market sentiment following recent corporate announcements [1] Group 1: Share Buyback Announcement - The board of Dechra Pharmaceuticals has approved a share buyback plan, allowing the company to repurchase shares in the open market for a total price of up to 40 million HKD [1] - The board believes that the share buyback demonstrates confidence in the company's business outlook and will ultimately benefit the company and create value for shareholders [1] Group 2: Drug Development Update - Dechra Pharmaceuticals' ATG-022 has received breakthrough therapy designation from the National Medical Products Administration for treating CLDN18.2 positive, HER2 negative unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma [1] - CMB International has raised its long-term and peak sales forecast for ATG-022 by nearly 30% and increased the company's DCF target price to 8.8 HKD, corresponding to a target market value of approximately 6 billion HKD and a peak sales revenue multiple of 2.1 times [1]
港股异动 | 德琪医药-B(06996)午后涨超10% 拟斥最多4000万港元回购股份 ATG-022获突破性治疗药物认定